Results 181 to 190 of about 153,159 (379)

Long term treatment with infliximab in pediatric Vogt-Koyanagi-Harada disease

open access: yesAmerican Journal of Ophthalmology Case Reports, 2018
Purpose: To report a case of pediatric Vogt-Koyanagi-Harada (VKH) successfully treated with infliximab and methotrexate for ten years. Observations: A 9-year-old Hispanic girl with VKH disease, was successfully treated with oral methotrexate 15 mg/week ...
Gustavo A. Budmann   +2 more
doaj  

Classification criteria for tubercular uveitis.

open access: yesAmerican journal of ophthalmology-glaucoma, 2021
The Standardization Of Uveitis Nomenclature Sun Wo   +12 more
semanticscholar   +1 more source

Minimally Invasive Glaucoma Surgery: Is It Here to Stay?

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT The advent of minimally invasive glaucoma surgery (MIGS) has expanded the treatment options available for glaucoma by providing options for reducing intraocular pressure without the serious complication profile associated with incisional glaucoma surgery.
Neeranjali Jain, Jennifer C. Fan Gaskin
wiley   +1 more source

A chromosome study of patients with uveitis treated with chlorambucil. [PDF]

open access: bronze, 1975
B.R. Reeves   +4 more
openalex   +1 more source

Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

open access: yesClinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background We aimed to describe 1‐year outcomes of eyes switched to faricimab from first‐generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age‐related macular degeneration (nAMD) in routine care. Methods Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness!
Adrian Hunt   +9 more
wiley   +1 more source

Classification criteria for Fuchs uveitis syndrome.

open access: yesAmerican journal of ophthalmology-glaucoma, 2021
The Standardization Of Uveitis Nomenclature Sun Working Group   +11 more
semanticscholar   +1 more source

PD‐L1 Promotes Immunological Tolerance and Enhances Visual Protection of hESC‐RPE Grafts in Retinal Degeneration

open access: yesCell Proliferation, EarlyView.
We generated immune‐tolerant mature hESC‐RPE cells by overexpressing PD‐L1. PD‐L1‐expressing hESC‐RPE grafts exhibited significantly higher survival, reduced apoptosis and enhanced visual protection in retinal degeneration models, which presents an alternative target to improve the efficiency of hESC‐RPE‐based therapy for AMD. ABSTRACT Immune rejection
Bowen Li   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy